Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART

JAMA

Volumn 293, Issue 7, 2005, Pages 817-829

  Nettles, Richard E ^a   Kieffer, Tara L ^a,e   Kwon, Patty ^a   Monie, Daphne ^a,f   Han, Yefei ^a   Parsons, Teresa ^a   Cofrancesco, Joseph ^a   Gallant, Joel E ^a   Quinn, Thomas C ^a,b   Jackson, Brooks ^a   Flexner, Charles ^a   Carson, Kathryn ^c   Ray, Stuart ^a   Persaud, Deborah ^a   Siliciano, Robert F ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^e VERTEX PHARMACEUTICALS   (United States)

^f Decision Resources Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VIREMIA; VIRUS LOAD;

EID: 13844274980     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.7.817     Document Type: Article

References (59)

1. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-739.
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
3. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387:188-191.
4. Bartlett JG, Lane HC. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington, DC: US Dept of Health and Human Services; 2004.
5. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002. JAMA. 2002;288:222-235.
6. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol. 1998;72:2422-2428.
7. Powderly WG, Saag MS, Chapman S, et al. Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999;13:1873-1880.
8. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 2001;286:171-179.
9. Raboud JM, Rae S, Woods R, et al. Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS. 2002;16:1627-1632.
10. Mira JA, Macias J, Nogales C, et al. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther. 2002;7:251-256.
11. Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia ("blips") in patients with previous suppression below the limits of quantification. AIDS. 2002;16:2035-2041.
12. Moore AL, Youle M, Lipman M, et al. Raised viral load in patients with viral suppression on highly active antiretroviral therapy. AIDS. 2002;16:615-618.
13. Greub G, Cozzi-Lepri A, Ledergerber B, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS. 2002;16:1967-1969.
14. Di Mascio M, Markowitz M, Louie M, et al. Viral blip dynamics during highly active antiretroviral therapy. J Virol. 2003;77:12165-12172.
15. Di Mascio M, Markowitz M, Louie M, et al. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. J Virol. 2004;78:10566-10573.
16. Di Mascio M, Ribeiro RM, Markowitz M, et al. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci. 2004;188:47-62.
17. Gunthard HF, Wong JK, Spina CA, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis. 2000;181:522-531.
18. Kolber MA, Gabr AH, De La Rosa A, et al. Genotypic analysis of plasma HIV-1 RNA after influenza vaccination of patients with previously undetectable viral loads. AIDS. 2002;16:537-542.
19. Easterbrook PJ, Ives N, Waters A, et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to <400 copies/mL. AIDS. 2002;16:1521-1527.
20. Gunthard HF, Frost SD, Leigh-Brown AJ, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol. 1999;73:9404-9412.
21. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat Med. 2000;6:82-85.
22. Cohen Stuart JW, Wensing AM, Kovacs C, et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr. 2001;28:105-113.
23. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282:1627-1632.
24. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/mL receiving combination therapy. JAMA. 2001;286:196-207.
25. Persaud D, Siberry GK, Ahonkhai A, et al. Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol. 2004;78:968-979.
26. Kieffer TL, Finucane MM, Nettles RE, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection. J Infect Dis. 2004;189:1452-1465.
27. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295-1300.
28. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 1997; 278:1291-1295.
29. Ruff CT, Ray SC, Kwon P, et al. Persistence of wildtype virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol. 2002;76:9481-9492.
30. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol. 2003;77:11212-11219.
31. Frenkel LM, Wang Y, Learn GH, et al. Multiple viral genetic analyses detect low-level human immunodeficiency virus type 1 replication during effective highly active antiretroviral therapy. J Virol. 2003;77:5721-5730.
32. + T cells in vivo. J Virol. 2005;79:1975-1980.
33. + T cells in vivo. J Virol. 2004;78:9105-9114.
34. Sterling TR, Lyles CM, Vlahov D, et al. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis. 1999;180:666-672.
35. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med. 1999;341:394-402.
36. Quinn TC, Wawer MJ, Sewankambo N, et al; Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342:921-929.
37. Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001;344:720-725.
38. Holodniy M, Mole L, Winters M, Merigan TC. Diurnal and short-term stability of HIV virus load as measured by gene amplification. J Acquir Immune Defic Syndr. 1994;7:363-368.
39. Deeks SG, Coleman RL, White R, et al. Variance in plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days. J Infect Dis. 1997;176:514-517.
40. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183-188.
41. Swofford DL. PAUP*, Phylogenetic Analysis Using Parsimony (*and Other Methods). Version 4b10. Sunderland, Mass: Sinauer; 2000. Available at: http: //paup.csit.fsu.edu/downl.html. Accessed March 6, 2002.
42. Saitou N, Nei M. The neighbor-joining method. Mol Biol Evol. 1987;4:406-425.
43. Felsenstein J. Confidence limits on phylogenies. Evolution. 1985;39:783-791.
44. Wain-Hobson S, Renoux-Elbe C, Vartanian JP, Meyerhans A. Network analysis of human and simian immunodeficiency virus sequence sets reveals massive recombination resulting in shorter pathways. J Gen Virol. 2003;84:885-895.
45. Huson DH. SplitsTree: analyzing and visualizing evolutionary data. Bioinformatics. 1998;14:68-73.
46. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R. DnaSP, DNA polymorphism analyses by the coalescent and other methods. Bioinformatics. 2003;19: 2496-2497.
47. Hammond J, Calef C, Larder B, et al. Los Alamos HIV Sequence Database: Mutations in Retroviral Genes Associated With Drug Resistance. 2004, Available at: http://www.hiv.lanl.gov. Accessibility verified January 10, 2005.
48. Shafer RW, Kantor R, Ree S, Gonzales M. Stanford HIV RT and Protease Sequence Database: HIV Drug Resistance Notes. 2004. Available at: http: //hivdb.stanford.edu. Accessibility verified January 10, 2005.
49. Lamotte C, Peytavin G, Farinotti R. Determination of nelfinavir, a potent HIV protease inhibitor, and its active metabolite M8 in human plasma by high-performance liquid chromatography with photodiode-array detection. J Chromatogr B Biomed Sci Appl. 1999;735:159-170.
50. Pav JW, Rowland LS, Korpalski DJ. HPLC-UV method for the quantitation of nevirapine in biological matrices following solid phase extraction. J Pharm Biomed Anal. 1999;20:91-98.
51. Crommentuyn KM, Mulder JW, Mairuhu AT, et al. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antivir Ther. 2004;9:779-785.
52. Roche Amplicor HIV-1 Monitor Test version 1.5 [package insert]. Indianapolis, Ind: Roche Diagnostics Corp; 2002.
53. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd ed. Oxford, England: Blackwell Scientific Publications; 1987.
54. Markowitz M, Louie M, Hurley A, et al. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol. 2003; 77:5037-5038.
55. Percus JK, Percus OE, Markowitz M, et al. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull Math Biol. 2003;65:263-277.
56. Jackson JB, Piwowar-Manning E, Johnson-Lewis L, et al. Comparison of versions 1.0 AND 1.5 of the UltraSensitive AMPLICOR HIV-1 MONITOR test for subjects with low viral load. J Clin Microbiol. 2004;42: 2774-2776.
57. Miller LG, Golin CE, Liu H, et al. No evidence of an association between transient HIV viremia ("blips") and lower adherence to the antiretroviral medication regimen. J Infect Dis. 2004;189: 1487-1496.
58. Parkin NT, Deeks SG, Wrin MT, et al. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS. 2000;14:2877-2887.
59. Aleman S, Soderbarg K, Visco-Comandini U, et al. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS. 2002;16:1039-1044.